Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No surprise, as Axis-Shield tells shareholders to reject Alere's "opportunistic and hostile" bid

This article was originally published in Clinica

Executive Summary

Axis-Shield's board of directors has formally instructed company shareholders to reject Alere’s takeover offer, maintaining that the bid of 460p per share represents "an unacceptably low multiple" that fundamentally undervalues its business. Axis-Shield described Alere’s offer as "opportunistic and hostile", and said it did not take into account: the benefits Axis-Shield is beginning to reap from its Afinion point-of-care (POC) testing platform; planned European launch of the firm’s Afinion lipid panel by the end of the year, which will give it access to a market which is estimated to grow to around $500m by 2013; the diabetes testing opportunity in Asia and emerging markets, where the company has placed over 21,000 of its NycoCard instruments, an older POC device. In Axis-Shield’s recently-reported first-half results, 43% year-on-year growth in Afinion sales helped drive overall revenues of £56.2m ($92.0m), up 10% over the same period last year (www.clinica.co.uk, 24 August 2011). In making its latest decision, Axis-Shield’s board has been advised by JP Morgan Cazenove.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel